Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000822132 | SCV000962920 | uncertain significance | Ataxia-telangiectasia syndrome | 2020-11-10 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with ATM-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change replaces asparagine with aspartic acid at codon 321 of the ATM protein (p.Asn321Asp). The asparagine residue is moderately conserved and there is a small physicochemical difference between asparagine and aspartic acid. |
| Ambry Genetics | RCV002381869 | SCV002694147 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-08-07 | criteria provided, single submitter | clinical testing | The p.N321D variant (also known as c.961A>G), located in coding exon 7 of the ATM gene, results from an A to G substitution at nucleotide position 961. The asparagine at codon 321 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |